{"product_id":"jspr-vrio-analysis","title":"Jasper Therapeutics, Inc. (JSPR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to sustained competitive advantage for Jasper Therapeutics, Inc. (JSPR) requires a deep dive into its core resources. This VRIO analysis distills whether the company's assets are truly Valuable, Rare, Inimitable, and Organized to create lasting success. Discover the critical factors driving - or hindering - Jasper Therapeutics, Inc. (JSPR)'s market position right now.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e1. Briquilimab’s Novel Mechanism of Action (KIT Antagonism)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset, Briquilimab, and trying to figure out if this targeted approach to mast cell diseases is a sustainable edge. Honestly, the mechanism itself - blocking Stem Cell Factor (SCF) from binding to the c-Kit receptor to induce mast cell apoptosis - is powerful because it targets the root cause, not just the symptoms. This is why we see deep responses in trials.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eValue\u003c\/strong\u003e here is clear: it offers a highly targeted approach where broader anti-inflammatories might fail. For Chronic Spontaneous Urticaria (CSU), for example, the Open-Label Extension (OLE) study showed a 73% complete response rate at week 12 for patients on the 180mg Q8W dose. That’s a concrete outcome that matters to patients and payers.\u003c\/p\u003e\n\u003cp\u003eAs for \u003cstrong\u003eRarity\u003c\/strong\u003e, targeting c-Kit specifically with a monoclonal antibody for these indications is relatively uncommon right now; most competitors are chasing broader inflammatory pathways. Still, the underlying biological insight isn't a total secret. The real rarity is in the execution - the specific, optimized, aglycosylated antibody structure that seems to mitigate unwanted mast cell activation while effectively depleting them.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eImitability\u003c\/strong\u003e factor is mixed. The core science is known, but Jasper Therapeutics has the intellectual property around the specific antibody construct, which acts as a moat. However, if a competitor cracked a similar, non-infringing mechanism, the core idea is imitable. The current differentiator is the clinical proof you’re seeing now, despite the recent hiccup with a drug product lot that affected some cohorts.\u003c\/p\u003e\n\u003cp\u003eRegarding \u003cstrong\u003eOrganization\u003c\/strong\u003e, the company has shown commitment by halting the ETESIAN asthma study and the SCID program to focus resources here. That’s good focus, but the July 2025 reorganization, cutting the workforce by about 50%, shows they are aggressively managing burn to survive. As of September 30, 2025, they had $50.89 million in cash, which needs to last until the planned Phase 2b CSU study starts mid-2026. They are definitely organized around this asset, but the financial runway requires tight control.\u003c\/p\u003e\n\u003cp\u003eThe resulting \u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. Briquilimab’s mechanism is differentiated, and the early efficacy data is compelling, but the advantage hinges on successfully navigating the remaining clinical hurdles and solidifying the data set, especially after the investigation into the anomalous results from the BEACON study.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the efficacy numbers we have to back up the 'Value' claim:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication \/ Study\u003c\/td\u003e\n\u003ctd\u003eDose \/ Schedule\u003c\/td\u003e\n\u003ctd\u003eKey Efficacy Metric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU (BEACON OLE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e180mg\u003c\/strong\u003e Q8W\u003c\/td\u003e\n\u003ctd\u003eComplete Response at Week 12\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU (BEACON Single Dose)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e240mg\/360mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComplete Response\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e89%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIndU (SPOTLIGHT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e180mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Response by Week 2\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsthma (ETESIAN)\u003c\/td\u003e\n\u003ctd\u003eSingle \u003cstrong\u003e180mg\u003c\/strong\u003e Dose\u003c\/td\u003e\n\u003ctd\u003eLate Asthmatic Response Improvement at 6 Weeks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the impact of the recent net loss of $-18.73 million in Q3 2025, which required a $30 million capital raise to extend the runway. Finance: draft the updated 13-week cash flow view incorporating the Q3 burn rate by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e2. Demonstrated High Efficacy in CSU (89% CR)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: The 89% complete response rate (UAS7=0) seen in certain single-dose cohorts of the BEACON study provides a powerful benchmark for future Phase 2b dose selection.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe BEACON Phase 1b\/2a study demonstrated rapid onset of deep clinical responses in adult participants with Chronic Spontaneous Urticaria (CSU) receiving briquilimab, a novel antibody therapy targeting KIT (CD117) to deplete mast cells.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDose Cohort\u003c\/th\u003e\n\u003cth\u003eParticipants (N)\u003c\/th\u003e\n\u003cth\u003eComplete Response (CR) Rate (UAS7=0)\u003c\/th\u003e\n\u003cth\u003eClinical Response Rate (by Week 2)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e240mg Single Dose\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e (5\/5)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e360mg Single Dose\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e75%\u003c\/strong\u003e (3\/4)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Single-Dose Cohorts\u003c\/td\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e89%\u003c\/strong\u003e (8\/9)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e78%\u003c\/strong\u003e (7\/9)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eMean Urticaria Activity Score over 7 days (UAS7) reductions from baseline at Week 4 were:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e240mg\u003c\/strong\u003e group: \u003cstrong\u003e-28.3\u003c\/strong\u003e points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e360mg\u003c\/strong\u003e group: \u003cstrong\u003e-22.9\u003c\/strong\u003e points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: An 89% complete response rate in a difficult-to-treat indication like Chronic Spontaneous Urticaria (CSU) is exceptionally rare for any therapy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe observed efficacy is supported by pharmacodynamic data showing early and sustained reductions in serum tryptase, which was observed in \u003cstrong\u003e80%\u003c\/strong\u003e of participants in the combined 240mg and 360mg cohorts, suggesting successful mast cell suppression.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Competitors can try to match the efficacy, but replicating this specific, high-performing data set is difficult.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe mechanism of action involves briquilimab blocking stem cell factor from binding to the cell-surface receptor KIT, leading to mast cell depletion via apoptosis, which removes the underlying source of the inflammatory response.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Management is using this data to drive the next study design, showing they are organizing around the positive signal.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement's organization around this signal includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlanning to enroll an additional \u003cstrong\u003e10-12\u003c\/strong\u003e patients across specific cohorts to ensure a robust data set for Phase 2b dose selection.\u003c\/li\u003e\n\u003cli\u003eThe commencement of the Phase 2b CSU registrational study is now expected in \u003cstrong\u003emid-2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2024, the company reported \u003cstrong\u003e$92.5 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained, if the Phase 2b study confirms this depth of response is reproducible.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDurability data from the open-label extension (OLE) study on the 180mg Q8W regimen showed:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e (8 of 11) participants achieving a complete response at 12 weeks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe initial single-dose data showed durability out to 8-12 weeks at the 240mg level.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e3. Targeted Aglycosylated Antibody Technology\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBriquilimab, a targeted aglycosylated monoclonal antibody, has demonstrated efficacy across multiple indications, with over \u003cstrong\u003e145\u003c\/strong\u003e dosed participants and healthy volunteers receiving the therapy to date.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChronic Spontaneous Urticaria (CSU) - BEACON Study (240mg\/360mg single dose cohorts): \u003cstrong\u003e89%\u003c\/strong\u003e (\u003cstrong\u003e8 of 9\u003c\/strong\u003e) achieved a complete response.\u003c\/li\u003e\n\u003cli\u003eCSU - BEACON Study (240mg single dose cohort at 8 weeks): \u003cstrong\u003e100%\u003c\/strong\u003e (\u003cstrong\u003eN=3\u003c\/strong\u003e) Complete Responses (UAS7 = 0).\u003c\/li\u003e\n\u003cli\u003eChronic Inducible Urticaria (CIndU) - SPOTLIGHT Study (180mg cohort): \u003cstrong\u003e92%\u003c\/strong\u003e (\u003cstrong\u003e11 of 12\u003c\/strong\u003e) achieved a complete response.\u003c\/li\u003e\n\u003cli\u003eAllergic Asthma - ETESIAN Study (single 180mg dose): LAR %FEV1 improvement of \u003cstrong\u003e+10.4%\u003c\/strong\u003e at \u003cstrong\u003e6 weeks\u003c\/strong\u003e and \u003cstrong\u003e+8.7%\u003c\/strong\u003e at \u003cstrong\u003e12 weeks\u003c\/strong\u003e versus baseline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe technology supports rapid onset of action, with serum tryptase reductions below the lower limit of quantification observed as early as week \u003cstrong\u003e1\u003c\/strong\u003e post-dosing in some cohorts.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\/Dose Cohort\u003c\/td\u003e\n\u003ctd\u003eEndpoint\u003c\/td\u003e\n\u003ctd\u003eResult\u003c\/td\u003e\n\u003ctd\u003eTimepoint\/N\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU (240mg\/360mg Single Dose)\u003c\/td\u003e\n\u003ctd\u003eComplete Response\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e89%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU (240mg Single Dose)\u003c\/td\u003e\n\u003ctd\u003eMean change in UAS7 from baseline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-26.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e8 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIndU (180mg Cohort)\u003c\/td\u003e\n\u003ctd\u003eClinical Response\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e (\u003cstrong\u003e12 of 12\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eWithin 8 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIndU (180mg Cohort)\u003c\/td\u003e\n\u003ctd\u003eNeutrophil Count Decrease (Grade 1\/2)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e (\u003cstrong\u003e6 of 12\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eResolved in median of \u003cstrong\u003e16 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific aglycosylation modification is proprietary to Jasper Therapeutics' development process for briquilimab. The company is a clinical-stage biotechnology firm with a Market Cap of \u003cstrong\u003e$47.85 million\u003c\/strong\u003e as of a recent report.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe intellectual property protection surrounding the exact structure and manufacturing process is a barrier. The company has experienced a -191.12% Return on Equity (ROE) (TTM). The Price to Book Ratio is reported as 4.45.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis technology is central to the briquilimab asset, which is being evaluated in CSU, Chronic Inducible Urticaria (CIndU), and allergic asthma. The company has \u003cstrong\u003e27\u003c\/strong\u003e employees. The Phase 2b trial timeline was impacted, with the expected commencement delayed to mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe technology provides a technical edge demonstrated by clinical outcomes such as the \u003cstrong\u003e100%\u003c\/strong\u003e clinical response rate in the 180mg CIndU cohort. The company reported Net Cash of \u003cstrong\u003e$49.20 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e4. Focused Clinical Pipeline (CSU, CIndU, Asthma)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e By discontinuing the SCID program and halting other clinical and preclinical programs, Jasper Therapeutics, Inc. concentrated resources on CSU and CIndU indications. The company halted enrollment in the ETESIAN study in asthma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The focus on three related indications (CSU, CIndU, and previously Asthma) provides a clear path, though the strategic pivot itself is not inherently rare in the biotechnology sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can pivot their focus, but this strategic clarity, supported by recent financial actions, is a current organizational strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The July 2025 reorganization executed a workforce reduction of approximately \u003cstrong\u003e50%\u003c\/strong\u003e of its current employees to extend cash runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a strategic choice that buys runway, not a unique scientific asset.\u003c\/p\u003e\n\u003cp\u003eThe focused pipeline development is supported by recent financial restructuring and clinical data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\/Study\u003c\/td\u003e\n\u003ctd\u003eStatus Post-Reorganization (July 2025)\u003c\/td\u003e\n\u003ctd\u003eRelevant Pre-Reorganization Data Point\u003c\/td\u003e\n\u003ctd\u003eDose\/Cohort Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Inducible Urticaria (CIndU) \/ SPOTLIGHT\u003c\/td\u003e\n\u003ctd\u003eContinuing\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e90%\u003c\/strong\u003e of patients responded positively (40mg and 120mg cohorts).\u003c\/td\u003e\n\u003ctd\u003eIn the \u003cstrong\u003e120mg\u003c\/strong\u003e group, \u003cstrong\u003e10 out of 12\u003c\/strong\u003e participants achieved a complete response.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Spontaneous Urticaria (CSU) \/ BEACON\u003c\/td\u003e\n\u003ctd\u003eContinuing\u003c\/td\u003e\n\u003ctd\u003eRegulatory clearance obtained in US\/EU to expand with a \u003cstrong\u003e360mg\u003c\/strong\u003e single-dose cohort.\u003c\/td\u003e\n\u003ctd\u003eEnrollment complete for the \u003cstrong\u003e360mg\u003c\/strong\u003e single-dose cohort.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsthma \/ ETESIAN\u003c\/td\u003e\n\u003ctd\u003eHalted\u003c\/td\u003e\n\u003ctd\u003eRegulatory clearance obtained in Canada and the EU for an asthma challenge study (prior to halt).\u003c\/td\u003e\n\u003ctd\u003eEnrollment halted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial metrics related to capital preservation and focus:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce reduction of approximately \u003cstrong\u003e50%\u003c\/strong\u003e executed in July 2025.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents totaled \u003cstrong\u003e$50.9 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e$30 million\u003c\/strong\u003e underwritten offering of common stock and warrants was successfully completed, extending cash runway through the first half of 2026.\u003c\/li\u003e\n\u003cli\u003eResearch and development expense for the three months ended September 30, 2025, was \u003cstrong\u003e$14.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expense for the three months ended September 30, 2025, was \u003cstrong\u003e$4.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ended September 30, 2025, was \u003cstrong\u003e$18.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e5. Extended Cash Runway (Post-Sept 2025 Financing)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe September 2025 financing event provided a critical capital infusion to support near-term operations and clinical advancement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: The $30 million gross proceeds from the underwritten public offering, priced on or about September 19, 2025, extends Jasper's cash runway through the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: Securing $30 million in gross proceeds following mid-year clinical setbacks demonstrates continued, albeit potentially costly, investor confidence in the core asset, briquilimab.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: The capital itself is fungible; however, this specific $30 million buffer, secured at this time, is currently unique to JSPR's balance sheet structure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: The successful execution of the offering, managed by TD Cowen as the sole book-running manager, demonstrates organizational capability in capital markets under duress.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: \u003cstrong\u003eTemporary\u003c\/strong\u003e. The runway is finite and is projected to be depleted based on pre-financing burn rates, necessitating further financing before Q3 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context from the period immediately preceding the financing closing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (R\u0026amp;D + G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe $30 million gross proceeds are intended for continued advancement of briquilimab clinical programs and general corporate purposes.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e6. Ongoing Clinical Data Generation (OLE Study)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The Open-Label Extension (OLE) study allows for continued, long-term safety and efficacy data collection, which is crucial for regulatory discussions and future dosing decisions.\u003c\/p\u003e\n\u003cp\u003eThe OLE study is designed to provide extended safety and efficacy data to inform the selection of a dose for the planned Phase 2b CSU study, which is now expected to commence mid-2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Maintaining an OLE while investigating trial anomalies shows commitment to data integrity.\u003c\/p\u003e\n\u003cp\u003eThe internal investigation into the BEACON study anomalies concluded that the anomalous efficacy results in two cohorts did not appear to be related to drug substance (“DS”) or drug product (“DP”) manufacturing or distribution processes. Final conclusions for this investigation are planned for Q4 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can run OLEs, but this one is directly linked to the ongoing BEACON investigation.\u003c\/p\u003e\n\u003cp\u003eThe OLE is collecting data from patients rolling over from the BEACON cohorts under investigation (240mg Q8W and 240mg\/180mg Q8W).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Clinical operations are organized to roll over patients, ensuring data continuity despite the temporary halt in new enrollment for some cohorts.\u003c\/p\u003e\n\u003cp\u003ePatients are rolled over from the BEACON and SPOTLIGHT studies into the OLE study to receive a 180mg dose on a Q8W schedule.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a process that yields data, which is only valuable until the data is fully analyzed.\u003c\/p\u003e\n\u003cp\u003eAdditional data from the OLE study, anticipated in the first half of Q1 2026, should be adequate to complete dose selection for the planned Phase 2b CSU study.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key statistical data points related to the OLE study and related BEACON cohorts:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eContext\/Timeframe\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOLE Dose\/Frequency\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e180mg\u003c\/strong\u003e on a \u003cstrong\u003eQ8W\u003c\/strong\u003e schedule\u003c\/td\u003e\n\u003ctd\u003eFor rolled-over CSU and CIndU patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU OLE Efficacy (Complete Response)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8 of 11\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eAt 12 weeks on 180mg Q8W.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU OLE Patient Count for Update\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e40\u003c\/strong\u003e CSU patients\u003c\/td\u003e\n\u003ctd\u003eExpected 20-plus weeks of efficacy\/safety data in early Q1 2026 update.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIndU OLE Patient Count for Update\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e15\u003c\/strong\u003e CIndU patients\u003c\/td\u003e\n\u003ctd\u003eExpected 15-plus weeks of efficacy\/safety data in Q1 update.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBEACON Investigation Cohorts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e240mg Q8W\u003c\/strong\u003e and \u003cstrong\u003e240mg\/180mg Q8W\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSubject of the investigation into anomalous efficacy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2b CSU Study Start Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDependent on OLE data analysis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on data generation include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe BEACON investigation involved 10 patients enrolled at U.S. sites who showed an unexpected lack of clinical response by week 12.\u003c\/li\u003e\n\u003cli\u003eThe company reported $50.9 million in cash and cash equivalents as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expense for the three months ended September 30, 2025, was $14.4 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e7. Management Experience in Biotech Turnaround\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The leadership team navigated a major clinical data confounder and a significant stock drop (reported as 64.6% on July 7, 2025, with another report noting a nearly 55% decline) while implementing a 50% workforce reduction and still securing new financing.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCrisis\/Response Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Decline (July 7, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64.6%\u003c\/strong\u003e (or nearly \u003cstrong\u003e55%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e50%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Financing Secured\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$30 million\u003c\/strong\u003e underwritten offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram Discontinuations\u003c\/td\u003e\n\u003ctd\u003eETESIAN (asthma), SCID, and other preclinical\/clinical programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Experience managing a crisis involving third-party manufacturing quality issues is unfortunately common but valuable when it happens. The specific issue involved a drug product lot compromising results in two dosing cohorts of the BEACON Phase 1b\/2a study, affecting 10 of 13 patients in those cohorts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This specific experience is not easily transferable to a new team overnight. The management team executed a complex restructuring involving:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe departure of Chief Medical Officer Dr. Edwin Tucker, with Dr. Daniel Adelman assuming the role of Acting CMO effective August 1, 2025.\u003c\/li\u003e\n\u003cli\u003eHalting multiple programs, including the ETESIAN asthma trial.\u003c\/li\u003e\n\u003cli\u003eA commitment to continue enrolling an additional 10-12 patients in confounded cohorts to ensure a robust data set.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The ability to execute a major restructuring and a capital raise in quick succession demonstrates operational resilience. The company reported a net loss of $18.7 million (basic and diluted net loss per share of $1.13) for the three months ended September 30, 2025. The restructuring aimed to extend the cash runway through H1 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Leadership quality is hard to measure but can be lost through attrition or poor decisions. The team demonstrated the capacity to pivot focus exclusively to chronic urticaria programs where efficacy was strong (e.g., 89% complete response in certain single-dose cohorts).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e8. Intellectual Property Protection for Briquilimab\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Patents covering the composition of matter and method of use for briquilimab provide a legal barrier against direct generic or biosimilar competition for a defined period. The potential value is underscored by the targeted market sizes, such as the Chronic Urticaria global market, estimated at \u003cstrong\u003e$2.45 billion\u003c\/strong\u003e in 2022, projected to reach \u003cstrong\u003e$7.5 billion\u003c\/strong\u003e by 2029 with a \u003cstrong\u003e15% CAGR\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Standard for a late-stage asset, but the breadth of the patent estate is what matters. The company's R\u0026amp;D investment, which was \u003cstrong\u003e$14.4 million\u003c\/strong\u003e for the three months ended September 30, 2025, supports the ongoing development and defense of this core asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Competitors cannot legally copy the patented aspects without licensing or waiting for expiration. The Stanford License Agreement for briquilimab expires on a country-by-country basis on the \u003cstrong\u003elast-to-expire valid claim\u003c\/strong\u003e of a licensed patent in such country. The company may be eligible for patent term extension under the Hatch-Waxman Amendments upon FDA marketing approval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Legal and IP functions must be actively defending and monitoring the portfolio, which is assumed for a clinical-stage company. As of September 30, 2025, the company maintained cash and cash equivalents of \u003cstrong\u003e$50.9 million\u003c\/strong\u003e to support operations, including IP defense activities, against a net loss of \u003cstrong\u003e$18.7 million\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained, as long as the patents remain valid and enforceable. The potential commercial value protected by the IP is substantial, as evidenced by the projected Asthma market size of approximately \u003cstrong\u003e$32.81 billion\u003c\/strong\u003e by 2032.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes relevant financial and market context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eSource Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Urticaria Market Size (2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.45 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Urticaria Market CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNext five years (from 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Value of Equity (Non-affiliates)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$281.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares of Common Stock Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15,022,122\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFebruary 25, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey aspects related to patent term and exclusivity include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEligibility for patent term extension of up to \u003cstrong\u003efive years\u003c\/strong\u003e in the U.S. under the Hatch-Waxman Amendments, compensating for regulatory review time.\u003c\/li\u003e\n\u003cli\u003eThe Stanford License Agreement termination is contingent on the \u003cstrong\u003elast-to-expire valid claim\u003c\/strong\u003e on a country-by-country basis.\u003c\/li\u003e\n\u003cli\u003eThe company's ability to pursue patent term extension is dependent upon exercising \u003cstrong\u003edue diligence\u003c\/strong\u003e during the regulatory process.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJasper Therapeutics, Inc. (JSPR) - VRIO Analysis: \u003cstrong\u003e9. Positive Preliminary Data in Asthma (ETESIAN Study)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Early data in a second indication (asthma) validates the platform's potential beyond CSU\/CIndU, broadening the total addressable market if development resumes.\u003c\/p\u003e\n\u003cp\u003eA single 180mg subcutaneous dose of briquilimab demonstrated an improvement in Late Asthmatic Response (LAR) of 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline in the ETESIAN Phase 1b study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having positive signals in two distinct mast cell-driven diseases is a strong platform validation.\u003c\/p\u003e\n\u003cp\u003ePositive signals observed in allergic asthma align with efficacy signals previously noted in Chronic Spontaneous Urticaria (CSU) trials, supporting the platform's mechanism targeting KIT (CD117).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The data itself is unique to Jasper Therapeutics, Inc.'s trials.\u003c\/p\u003e\n\u003cp\u003eSpecific objective measures of efficacy are unique to the trial's execution and analysis:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBriquilimab Result\u003c\/td\u003e\n\u003ctd\u003ePlacebo Result\u003c\/td\u003e\n\u003ctd\u003eTime Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAR %Max FEV1 Improvement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 Weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAR %Max FEV1 Improvement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12 Weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMethacholine PD20 Response Shift\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.63\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.40\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWeek \u003cstrong\u003e6\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMethacholine PD20 Response Shift\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.58\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.60\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWeek \u003cstrong\u003e12\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is planning to present this data in December 2025, showing they are organizing to leverage it.\u003c\/p\u003e\n\u003cp\u003eThe preliminary data from the ETESIAN study, which involved approximately 17 participants across six sites in Canada, was announced on December 2, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The data is preliminary, and the asthma program was paused due to material concerns, so its value is currently contingent.\u003c\/p\u003e\n\u003cp\u003eThe ETESIAN study was halted and asthma development paused due to a defective drug product lot used in the trial; the internal investigation into this issue was reported as completed as of the data announcement. The company concluded the issue was due to patient selection in other cohorts, not drug efficacy.\u003c\/p\u003e\n\u003cp\u003eFinance: Draft the Q4 2025 cash burn projection, incorporating the September financing proceeds, by Friday.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and equivalents as of September 30, 2025: \u003cstrong\u003e$50.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancing Proceeds: Completed a $30 million underwritten offering.\u003c\/li\u003e\n\u003cli\u003eProjected Runway Extension: Through H1 2026.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Operating Expenses: Research and development expense was \u003cstrong\u003e$14.4 million\u003c\/strong\u003e; General and administrative expense was \u003cstrong\u003e$4.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$18.7 million\u003c\/strong\u003e (Loss per share $1.13).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516192350357,"sku":"jspr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/jspr-vrio-analysis.png?v=1740187028","url":"https:\/\/dcf-model.com\/fr\/products\/jspr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}